EUCTR2004-000248-25-ES进行中（未招募）不适用
A multinational, multicenter, randomized, double-blind,double-dummy, stratified, active controlled parallel groupstudy comparing the efficacy and safety of intravenouszoledronic acid, 5 mg once yearly, and oral risedronate, 5mg daily, in the prevention and treatment of corticosteroidinduced osteoporosis - 2306
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(for full list see protocol):
- •Male and female patients 18 to 85 years age old
- •Patients treated with at least 7.5 mg of oral prednisone per day (or equivalent systemic corticosteroid) and expected to continue corticosteroids therapy for at least a 12 month period:
- •Treated for less or equal to 3 months prior to study entry (prevention sub-population)
- •Treated for more than 3 months prior to study entry (treatment sub-population).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •(for full list see protocol):
- •Any prior use of bisphosphonate preparations except according to the washout schedule at
- •time of randomization:
- •2 years (if use >48 weeks)
- •1 year (if used >8 weeks but <48 weeks)
- •6 months (if used >2 weeks but <8 weeks)
- •2 months (if used <2 weeks)
- •Any prior use of i.v. bisphosphonate within 2 years prior to randomization
研究者
相似试验
进行中（未招募）
1 期
A clinical study in subjects with relapsing-remitting multiple sclerosis(RRMS) consisting of two parts:First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).Relapsing remitting multiple sclerosisMedDRA version: 14.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-003647-30-GRTeva Pharmaceutical Industries Ltd1,800
进行中（未招募）
1 期
A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the efficacy, tolerability and safety of two doses of laquinimod orally administered in relapsing remitting (R-R) multiple sclerosis (MS) subjectsRelapsing Remitting Multiple SclerosisMedDRA version: 5.1Level: PTClassification code 10028245EUCTR2004-003943-28-ESTeva Pharmaceutical Industries Ltd264
进行中（未招募）
1 期
A clinical study in subjects with relapsing-remitting multiple sclerosis(RRMS) consisting of two parts:First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).Relapsing remitting multiple sclerosisMedDRA version: 14.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-003647-30-BETeva Pharmaceutical Industries Ltd2,199
进行中（未招募）
不适用
A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the efficacy, tolerability and safety of two doses of laquinimod orally administered in relapsing remitting (R-R) multiple sclerosis (MS) subjectsRelapsing Remitting Multiple SclerosisMedDRA version: 5.1Level: PTClassification code 10028245EUCTR2004-003943-28-CZTeva Pharmaceutical Industries Ltd264
进行中（未招募）
不适用
A multinational, multicenter, randomized, double-blind,double-dummy, stratified, active controlled parallel groupstudy comparing the efficacy and safety of intravenouszoledronic acid, 5 mg once yearly, and oral risedronate, 5mg daily, in the prevention and treatment of corticosteroidinduced osteoporosis - 2306corticosteroid induced osteoporosisEUCTR2004-000248-25-CZovartis Pharma AG900